Hepatitis C Community
ursodeoxycholic acid and hep c
About This Community:

This forum is for questions about medical issues and research aspects of Hepatitis C such as, questions about being newly diagnosed, questions about current treatments, information and participation in discussions about research studies and clinical trials related to Hepatitis. If you would like to communicate with other people who have been touched by Hepatitis, please visit our new Hepatitis Social/Living with Hepatitis forum

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

ursodeoxycholic acid and hep c

One thing that HR told me when I recently went to see him was that ursodeoxycholic acid is important for hep c patients to take.

http://www.hivandhepatitis.com/hep_c/news/2007/070607_a.html


"Combination therapy with pegylated interferon (Pegasys or PegIntron) plus ribavirin has improved treatment for chronic hepatitis C, but many patients -- especially those with genotype 1 HCV -- fail to achieve sustained virological response. Such individuals could benefit from therapies that reduce liver inflammation and fibrosis, even if they do not produce virological suppression.

As reported in the June 25, 2007 advance online edition of Gut, researchers from the University of Tokyo assessed the effect of oral ursodeoxycholic acid (UDCA) on serum biomarkers in non-responders to prior interferon-based therapy. Chronic hepatitis C patients with elevated alanine aminotransferase (ALT) levels were randomly assigned to receive UDCA at doses of 150 mg/day (n = 199), 600 mg/day (n = 200), or 900 mg/day (n = 197) for 24 weeks. Changes in ALT, aspartate aminotransferase (AST), and gamma-glutamyl transpeptidase (GGT) were measured.

Results

• ALT, AST, and GGT levels decreased at week 4, then remained constant for the remainder of the drug administration period.

• The median changes in the UDCA 150, 600, and 900 mg/day dose groups, respectively, were:

- ALT: -15.3%, -29.2%, and -36.2%;
- AST: -13.6%, -25.0%, and -29.8%%;
- GGT: -22.4%, -41.0%, and -50.0%.

• All 3 biomarkers decreased significantly less in the UDCA 150 mg/day arm compared with the 2 higher dose groups.

• While changes in ALT and AST did not differ between the 600 and 900 mg/day dose groups, GGT was significantly lower in the 900 mg/day group.

• In a subgroup analysis, ALT decreased significantly in the 900 mg/day group when baseline GGT exceeded 80 IU/L.

• Serum HCV RNA levels did not change in any group.

• Adverse side effects were reported by 19.1% of the patients, with no differences between the 3 dose groups.

Conclusion

In conclusion, the authors wrote, "A 600 mg/day UDCA dose was optimal to decrease ALT and AST levels in chronic hepatitis C patients. The 900 mg/day dose decreased GGT levels further, and may be preferable in patients with prevailing biliary injuries."
Related Discussions
2 Comments Post a Comment
Blank
Avatar_m_tn
Here's the full study:

http://gut.bmj.com/content/56/12/1747.full.pdf
Blank
Avatar_m_tn
"Adverse side effects were reported by 19.1% of the patients, with no differences between the 3 dose groups."

In the study they elucidate that diarhoea was the most common adverse reaction and there were no severe adverse reactions.

The study is pretty impressive.

But, after looking around, it also appears to be very expensive.
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis C Community Resources
RSS Expert Activity
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
242532_tn?1269553979
Blank
3 Reasons Why You are Still Binge E...
Jul 14 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating: What Your Closet ...
Jul 09 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_f_tn
Blank
dontworry_behappy1
163305_tn?1333672171
Blank
orphanedhawk
Rural Mural, CA
Avatar_f_tn
Blank
nan535
Brooklyn, NY
446474_tn?1404424777
Blank
HectorSF
CA
1815939_tn?1377995399
Blank
pooh55811
96938_tn?1189803458
Blank
FlGuy
South, FL